World's Best Scientists 2026 revealed!
Award Badge
Medicine
Netherlands
2023

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 137 1859 1731 70 69 832 103403

Jaap Verweij publications per year

The chart shows the history of publications by Jaap Verweij between 1985 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Jaap Verweij published across 41 years, from 1985 to 2025, averaging 23.2 papers a year. Output peaked at 111 publications in 2023. 6 of the 953 publications appeared in the last two years.

No. of publications
25 50 75 100
Bar chart. Horizontal axis: year, 1985 to 2025. Vertical axis: number of publications, 0 to 111. Peak 111 publications in 2023. 1985: 1 publication 1986: 2 publications 1987: 6 publications 1988: 7 publications 1989: 12 publications 1990: 14 publications 1991: 17 publications 1992: 14 publications 1993: 36 publications 1994: 27 publications 1995: 26 publications 1996: 37 publications 1997: 34 publications 1998: 30 publications 1999: 35 publications 2000: 43 publications 2001: 26 publications 2002: 40 publications 2003: 36 publications 2004: 50 publications 2005: 47 publications 2006: 47 publications 2007: 33 publications 2008: 32 publications 2009: 34 publications 2010: 29 publications 2011: 27 publications 2012: 34 publications 2013: 18 publications 2014: 17 publications 2015: 10 publications 2016: 2 publications 2017: 1 publication 2018: 3 publications 2019: 4 publications 2020: 3 publications 2021: 1 publication 2022: 1 publication 2023: 111 publications 2024: 4 publications 2025: 2 publications
1985 2025

953 publications in total across all disciplines

View publications per year as a table
Jaap Verweij: publications per year, 1985 to 2025
Year Publications
1985 1
1986 2
1987 6
1988 7
1989 12
1990 14
1991 17
1992 14
1993 36
1994 27
1995 26
1996 37
1997 34
1998 30
1999 35
2000 43
2001 26
2002 40
2003 36
2004 50
2005 47
2006 47
2007 33
2008 32
2009 34
2010 29
2011 27
2012 34
2013 18
2014 17
2015 10
2016 2
2017 1
2018 3
2019 4
2020 3
2021 1
2022 1
2023 111
2024 4
2025 2
Total 953
Download as CSV

Jaap Verweij publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jaap Verweij sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 821–840 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 832 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186 832
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Jaap Verweij D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jaap Verweij sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 136–137 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 137 D-Index — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159 137
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Research.com Recognitions

  • 2023 - Research.com Medicine in Netherlands Leader Award
  • 2011 - Royal Netherlands Academy of Arts and Sciences

Overview

Jaap Verweij is affiliated with Erasmus University Rotterdam in the Netherlands, where the primary focus of their research is in the field of Medicine, with particular expertise in Oncology, Cancer Research, and Epidemiology. Their work spans a range of subfields such as Economics and Econometrics, Pulmonary and Respiratory Medicine, and several intersecting areas of cancer research and health systems analysis.

The scientist's research addresses topics including Cancer Genomics and Diagnostics, Cervical Cancer and HPV Research, Health Systems and Economic Evaluations, Genetic factors in colorectal cancer, Colorectal and Anal Carcinomas, Economic and Financial Impacts of Cancer, and Pharmaceutical Economics and Policy. This breadth of topics indicates engagement with both biomedical and systemic approaches to cancer and healthcare.

Key recent publications by Verweij demonstrate a focus on cancer biology and health outcomes:

  • "Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site," 2020, British Journal of Cancer
  • "Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe," 2020, Cancers
  • "Empowering effective biomarker-driven precision oncology: A call to action," 2024, European Journal of Cancer
  • "Ektacytometry Analysis of Post-splenectomy Red Blood Cell Properties Identifies Cell Membrane Stability Test as a Novel Biomarker of Membrane Health in Hereditary Spherocytosis," 2021, Frontiers in Physiology
  • "StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs)," 2024, Journal of Clinical Oncology

Frequent collaborators in Verweij's work include B. Dekeyser, Barend J. Sikkema, Peter de Bruijn, F. Wastelin, and François Zammit, each contributing to multiple publications. This suggests a consistent research network supporting studies across oncology, pharmacology, and related biomedical fields.

Verweij has published extensively in recognized venues such as the British Journal of Cancer, European Journal of Cancer, Cancers, Frontiers in Physiology, and the Journal of Clinical Oncology. These publication venues reflect the multidisciplinary nature of their research spanning clinical oncology, physiology, and cancer policy evaluation.

In recognition of contributions to science, Jaap Verweij was awarded membership by the Royal Netherlands Academy of Arts and Sciences in 2011. This accolade indicates peer recognition within the Netherlands scientific community.

Best Publications

  • New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

    Elizabeth Eisenhauer;Patrick Therasse;Jan Bogaerts;L.H. Schwartz

  • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

    George D Demetri;Allan T van Oosterom;Christopher R Garrett;Martin E Blackstein

  • Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

    Hans Gelderblom;Jaap Verweij;Kees Nooter;Alex Sparreboom

  • Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial*

    Jaap Verweij;Paolo G. Casali;John Zalcberg;Axel LeCesne

  • Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

    Allan T van Oosterom;Ian Judson;Jaap Verweij;Sigrid Stroobants

  • KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

    Maria Debiec-Rychter;Raf Sciot;Axel Le Cesne;Marcus Schlemmer

  • Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

    Ian Judson;Jaap Verweij;Hans Gelderblom;Jörg T Hartmann;Jörg T Hartmann

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer―Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

    Stefan Sleijfer;Isabelle Ray-Coquard;Zsuzsa Papai;Axel Le Cesne

  • Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

    Albert J ten Tije;Jaap Verweij;Walter J Loos;Alex Sparreboom;Alex Sparreboom

  • Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors

    Johanna C. Bendell;Jordi Rodon;Howard A. Burris;Maja de Jonge

  • Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

    Isabelle Ray-Coquard;Claire Cropet;Martine Van Glabbeke;Catherine Sebban

  • Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

    M. Van Glabbeke;A.T. van Oosterom;J.W. Oosterhuis;H. Mouridsen

  • Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study

    Rolf D Issels;Lars H Lindner;Jaap Verweij;Peter Wust

  • Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

    A Santoro;T Tursz;H Mouridsen;Jaap Verweij

  • Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

    Andrea Ardizzoni;Heine Hansen;Per Dombernowsky;Teresa Gamucci

  • Soft Tissue Sarcomas of Adults State of the Translational Science

    Ernest C. Borden;Laurence H. Baker;Robert S. Bell;Vivien Bramwell

  • Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

    J Verweij;A van Oosterom;J.-Y Blay;I Judson

  • Effects of St. John's Wort on Irinotecan Metabolism

    Ron H. J. Mathijssen;Jaap Verweij;Peter de Bruijn;Walter J. Loos

  • Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

    G J Creemers;G Bolis;M Gore;G Scarfone

Frequent Co-Authors

Alex Sparreboom
Alex Sparreboom The Ohio State University
Ron H.J. Mathijssen
Ron H.J. Mathijssen Erasmus University Rotterdam
Stefan Sleijfer
Stefan Sleijfer Erasmus University Rotterdam
Ian Judson
Ian Judson Institute of Cancer Research
Hans Gelderblom
Hans Gelderblom Leiden University Medical Center
Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Sharyn D. Baker
Sharyn D. Baker The Ohio State University
Paolo G. Casali
Paolo G. Casali University of Milan
Axel Le Cesne
Axel Le Cesne Institut Gustave Roussy

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online education options can open many doors for aspiring healthcare professionals. For registered nurses looking to advance their credentials without breaking the bank, the cheapest rn to bsn online programs are worth considering. These affordable BSN programs provide flexibility and allow working nurses to continue their education on their own schedule.

Those without a nursing background who are aiming for advanced roles may benefit from direct entry msn programs for non nurses online. These programs are designed for individuals with a bachelor's degree in another field, helping them make a swift transition into nursing.

If you’re just starting your journey and seeking accessible entry points, learning about the easiest rn program can guide you towards schools with higher acceptance rates and less competitive admissions.

Beyond nursing, the healthcare field also needs skilled professionals in administration. Accredited medical billing and coding online schools with financial aid can help students join this in-demand sector, all from the convenience of home.

Best Scientists Citing Jaap Verweij

Trending Scientists

Recently Published Articles